Recursion Pharmaceuticals (RXRX) expanded its partnership with Citeline to improve its AI-enabled ClinTech platform, Citeline said Tuesday.
Under the deal, Citeline's multi modal datasets will be integrated with Recursion's end-to-end platform to support clinical trial design, site selection and development decision-making, the company said.
Financial terms of the partnership were not disclosed.
Recursion Pharmaceuticals shares were more than 4% higher in Tuesday trading.
Price: 2.97, Change: +0.13, Percent Change: +4.58